Trial Profile

A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Indoximod (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Etoposide
Indications Brain cancer; CNS cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioma; Medulloblastoma
Focus Adverse reactions; Therapeutic Use
Sponsors NewLink Genetics Corporation

Most Recent Events

04 Jun 2024 Results of pooled analysis studying effect of indoximod-based chemo-immunotherapy((n=27, NCT02502708, NCT04049669) or (n=3, NCT05106296)) , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
03 Jun 2020 Status changed from active, no longer recruiting to completed.
23 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com